Replay available

Pulmonx Corporation (LUNG) Q3 2025 Earnings Call

Pulmonx Corporation (NASDAQ: LUNG) Q3 2025 earnings conference call, held 2025-11-12. Replay captured from the company's public earnings webcast.

Wed, November 12, 2025 at 4:30 PMendedReplay
Pulmonx Corporation (LUNG) Q3 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Lane Morgan

Investor Relations

Glenn French

President and Chief Executive Officer

Derek Sung

Chief Operating Officer and Chief Financial Officer

Nathan Trebek

Analyst, Wells Fargo Securities

John Young

Analyst, Tenacore

Jason Vettner

Analyst, Piper Sandler

Replay transcript excerpt

Hello, and thank you for standing by. Welcome to Pullman Next Third Quarter 2025 Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask the question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. I would now like to hand the conference over to Lane Morgan, you may begin. Good afternoon, and thank you for participating in today's call. Joining me from Pomonix are Glenn French, President and Chief Executive Officer, and Derek Son, Chief Operating Officer and Chief Financial Officer. Earlier today, Pomonix issued a press release announcing its financial results for the quarter ended September 30th, 2025. A copy of the press release is available on Pomonix's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation, those relating to our operating trends, commercial strategies, and future financial performance, including long-term outlook and full-year 2025 guidance, the timing and results of clinical trials, physician engagement, expense management, market opportunity, guidance for revenue, gross margin and operating expenses, commercial expansion and product de...

More from Pulmonx Corporation